Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

INMB INmune Bio Inc. Common stock
$0.95 -9.87% -0.10
Notify me if price changes either direction
Interactive Brokers Logotype

Buy INMB stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

INmune Bio Inc. Common stock (INMB)

Loading

Key Stats

Market cap. 29.3M
Enterprise value 17.4M
Trailing PE -0.50962365442707
Forward PE -2.4418602
PEG Ratio 0.0053510483714842
Enterprise to EBITDA -0.992
Enterprise to revenue 347.76064
Price to book MRQ 1.6228747
Price to sales TTM 585.99344

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 50000
EBITDA -17524000
Diluted EPS TTM -0.6
Total Cash (MRQ) 16.3M
Current ratio (MRQ) 6.413
Operating Cash Flow (TTM) -12913000

INMB trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent INMB News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.